Is RNXT or LENZ more profitable?

LENZ Therapeutics has a net margin of -519.30% compared to RenovoRx's net margin of -823.98%. LENZ Therapeutics' return on equity of -46.82% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% LENZ Therapeutics -519.30% -46.82% -43.32%

Does the media favor RNXT or LENZ?

In the previous week, LENZ Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for LENZ Therapeutics and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat LENZ Therapeutics' score of -0.32 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACB or RNXT?

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is ACB or RNXT more profitable?

Aurora Cannabis has a net margin of -33.57% compared to RenovoRx's net margin of -823.98%. Aurora Cannabis' return on equity of 0.10% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -33.57% 0.10% 0.07% RenovoRx -823.98% -135.03% -101.92%

Does the media prefer MOLN or RNXT?

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ORMP or RNXT?

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media refer more to MIST or RNXT?

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 1 mentions for RenovoRx. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat RenovoRx's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RenovoRx (RNXT) Competitors

$0.88 +0.01 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.05%)

As of 04:10 PM Eastern

Compare

RNXT vs. LENZ, ACB, MOLN, ORMP, and MIST

Should you buy RenovoRx stock or one of its competitors? MarketBeat compares RenovoRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RenovoRx include LENZ Therapeutics (LENZ), Aurora Cannabis (ACB), Molecular Partners (MOLN), Oramed Pharmaceuticals (ORMP), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry.

How does RenovoRx compare to LENZ Therapeutics?

RenovoRx (NASDAQ:RNXT) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

LENZ Therapeutics has a net margin of -519.30% compared to RenovoRx's net margin of -823.98%. LENZ Therapeutics' return on equity of -46.82% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

RenovoRx has higher earnings, but lower revenue than LENZ Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A
LENZ Therapeutics	$19.09M	8.47	-$82.13M	-$3.60	N/A

RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 868.55%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 477.52%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, LENZ Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for LENZ Therapeutics and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat LENZ Therapeutics' score of -0.32 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RenovoRx beats LENZ Therapeutics on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, RenovoRx had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Overall Sentiment
Aurora Cannabis	Neutral
RenovoRx	Neutral

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aurora Cannabis has a net margin of -33.57% compared to RenovoRx's net margin of -823.98%. Aurora Cannabis' return on equity of 0.10% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
RenovoRx	-823.98%	-135.03%	-101.92%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aurora Cannabis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

RenovoRx has lower revenue, but higher earnings than Aurora Cannabis. RenovoRx is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	0.66	-$88.13M	-$1.56	N/A
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A

Summary

RenovoRx beats Aurora Cannabis on 10 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RenovoRx has lower revenue, but higher earnings than Molecular Partners. RenovoRx is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.44	-$74.41M	-$1.94	N/A
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A

Molecular Partners has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Molecular Partners' return on equity of -66.62% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
RenovoRx	-823.98%	-135.03%	-101.92%

Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Molecular Partners currently has a consensus price target of $8.38, indicating a potential upside of 110.43%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Molecular Partners and RenovoRx tied by winning 7 of the 14 factors compared between the two stocks.

How does RenovoRx compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Oramed Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Oramed Pharmaceuticals' return on equity of -5.37% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
RenovoRx	-823.98%	-135.03%	-101.92%

Oramed Pharmaceuticals has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	82.27	$64.05M	$2.59	1.55
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A

Oramed Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
RenovoRx	Neutral

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats RenovoRx on 11 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Milestone Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
RenovoRx	-823.98%	-135.03%	-101.92%

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RenovoRx has lower revenue, but higher earnings than Milestone Pharmaceuticals. RenovoRx is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 1 mentions for RenovoRx. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat RenovoRx's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 489.43%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 868.55%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Milestone Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats RenovoRx on 9 of the 16 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.91M	$3.63B	$6.81B	$12.32B
Dividend Yield	N/A	2.19%	2.67%	9.67%
P/E Ratio	-2.66	20.62	26.97	24.18
Price / Sales	35.30	306.28	518.57	96.01
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	5.85	8.17	10.67	6.25
Net Income	-$11.17M	$23.81M	$3.60B	$331.66M
7 Day Performance	3.25%	-1.16%	-0.37%	-1.10%
1 Month Performance	-4.61%	2.59%	1.80%	-1.29%
1 Year Performance	-31.97%	45.43%	25.50%	18.84%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	3.3415 of 5 stars	$0.88 +1.6%	$8.50 +868.6%	-33.6%	$38.91M	$1.12M	N/A	6	Analyst Upgrade
LENZ LENZ Therapeutics	2.4939 of 5 stars	$4.93 -5.7%	$29.80 +504.5%	-85.3%	$163.98M	$19.09M	N/A	110
ACB Aurora Cannabis	0.9636 of 5 stars	$2.66 -0.4%	N/A	-42.8%	$163.79M	$247.82M	N/A	1,028
MOLN Molecular Partners	2.3843 of 5 stars	$3.97 -1.0%	$8.38 +111.0%	+10.3%	$161.90M	$5.65M	N/A	180
ORMP Oramed Pharmaceuticals	1.1331 of 5 stars	$4.00 +1.3%	N/A	+93.4%	$161.86M	$2M	1.54	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. LENZ, ACB, MOLN, ORMP, and MIST

How does RenovoRx compare to LENZ Therapeutics?

Summary

How does RenovoRx compare to Aurora Cannabis?

Summary

How does RenovoRx compare to Molecular Partners?

Summary

How does RenovoRx compare to Oramed Pharmaceuticals?

Summary

How does RenovoRx compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. LENZ, ACB, MOLN, ORMP, and MIST

How does RenovoRx compare to LENZ Therapeutics?

Is RNXT or LENZ more profitable?

Do institutionals & insiders hold more shares of RNXT or LENZ?

Which has preferable valuation & earnings, RNXT or LENZ?

Which has more volatility & risk, RNXT or LENZ?

Do analysts rate RNXT or LENZ?

Does the media favor RNXT or LENZ?

Summary

How does RenovoRx compare to Aurora Cannabis?

Does the media prefer ACB or RNXT?

Do analysts rate ACB or RNXT?

Is ACB or RNXT more profitable?

Do institutionals & insiders believe in ACB or RNXT?

Which has more risk & volatility, ACB or RNXT?

Which has stronger valuation & earnings, ACB or RNXT?

Summary

How does RenovoRx compare to Molecular Partners?

Does the media prefer MOLN or RNXT?

Do institutionals and insiders believe in MOLN or RNXT?

Which has stronger earnings & valuation, MOLN or RNXT?

Is MOLN or RNXT more profitable?

Which has more risk & volatility, MOLN or RNXT?

Do analysts prefer MOLN or RNXT?

Summary

How does RenovoRx compare to Oramed Pharmaceuticals?

Is ORMP or RNXT more profitable?

Which has better earnings & valuation, ORMP or RNXT?

Which has more volatility & risk, ORMP or RNXT?

Do analysts recommend ORMP or RNXT?

Does the media prefer ORMP or RNXT?

Do insiders & institutionals believe in ORMP or RNXT?

Summary

How does RenovoRx compare to Milestone Pharmaceuticals?

Is MIST or RNXT more profitable?

Do insiders & institutionals have more ownership in MIST or RNXT?

Which has preferable earnings and valuation, MIST or RNXT?

Does the media refer more to MIST or RNXT?

Do analysts rate MIST or RNXT?

Which has more risk and volatility, MIST or RNXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools